Clinical Trials Logo

Recurrent Breast Cancer clinical trials

View clinical trials related to Recurrent Breast Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06369285 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

ALISCA-Breast1
Start date: December 31, 2024
Phase: Phase 2
Study type: Interventional

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.

NCT ID: NCT06202118 Not yet recruiting - Breast Cancer Clinical Trials

A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.

Start date: February 2024
Phase: N/A
Study type: Interventional

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of newly diagnosed or Recurrent Breast Carcinoma in frail or elderly patients.